CN114340659B - 联合治疗 - Google Patents

联合治疗 Download PDF

Info

Publication number
CN114340659B
CN114340659B CN202080044905.2A CN202080044905A CN114340659B CN 114340659 B CN114340659 B CN 114340659B CN 202080044905 A CN202080044905 A CN 202080044905A CN 114340659 B CN114340659 B CN 114340659B
Authority
CN
China
Prior art keywords
administration
melanoma
weeks
mrna
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080044905.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114340659A (zh
Inventor
M·库尔斯
T·梵德阿斯彻
B·德克斯马埃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ezer Arne Immunotherapy Co ltd
Original Assignee
Ezer Arne Immunotherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ezer Arne Immunotherapy Co ltd filed Critical Ezer Arne Immunotherapy Co ltd
Publication of CN114340659A publication Critical patent/CN114340659A/zh
Application granted granted Critical
Publication of CN114340659B publication Critical patent/CN114340659B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080044905.2A 2019-06-27 2020-06-29 联合治疗 Active CN114340659B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19182813.6 2019-06-27
EP19182813 2019-06-27
PCT/EP2020/068217 WO2020260685A1 (en) 2019-06-27 2020-06-29 Combination therapy

Publications (2)

Publication Number Publication Date
CN114340659A CN114340659A (zh) 2022-04-12
CN114340659B true CN114340659B (zh) 2024-06-25

Family

ID=67253658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044905.2A Active CN114340659B (zh) 2019-06-27 2020-06-29 联合治疗

Country Status (12)

Country Link
US (1) US20220387573A1 (https=)
EP (1) EP3990008A1 (https=)
JP (1) JP2022540759A (https=)
KR (1) KR20220061946A (https=)
CN (1) CN114340659B (https=)
AU (1) AU2020301582A1 (https=)
BR (1) BR112021025170A2 (https=)
CA (1) CA3144296A1 (https=)
IL (1) IL289130A (https=)
MX (1) MX2021015802A (https=)
WO (1) WO2020260685A1 (https=)
ZA (1) ZA202200731B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386843A1 (en) * 2019-01-04 2021-12-16 Etherna Immunotherapies Nv mRNA Vaccine
WO2020182993A1 (en) * 2019-03-13 2020-09-17 Etherna Immunotherapies Nv Mrna vaccine
WO2025260013A1 (en) * 2024-06-13 2025-12-18 Yale University Compositions and methods of mrna-based adjuvants for mrna vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP2201100B1 (en) * 2007-09-14 2016-03-16 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
AU2017257254B2 (en) * 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.;Ana Maria Arance Fernandez et al;《Journal of Clinical Oncology》;第第37卷卷(第第15期期);第2641页 *

Also Published As

Publication number Publication date
CN114340659A (zh) 2022-04-12
BR112021025170A2 (pt) 2022-01-25
IL289130A (en) 2022-02-01
WO2020260685A1 (en) 2020-12-30
EP3990008A1 (en) 2022-05-04
AU2020301582A1 (en) 2022-02-03
ZA202200731B (en) 2022-09-28
KR20220061946A (ko) 2022-05-13
US20220387573A1 (en) 2022-12-08
CA3144296A1 (en) 2020-12-30
JP2022540759A (ja) 2022-09-20
MX2021015802A (es) 2022-04-01

Similar Documents

Publication Publication Date Title
Ahern et al. Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy
Crosby et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
Saranga‐Perry et al. Recent developments in the medical and surgical treatment of melanoma
CN114207117A (zh) 用于调节巨噬细胞活性的方法
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
US11851492B2 (en) Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
JP2018538265A (ja) 癌を治療するための方法及び組成物
CN114340659B (zh) 联合治疗
Maeng et al. Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy
CN114555110A (zh) 与免疫检查点抑制剂组合的免疫调节性il-2剂
US20220033513A1 (en) Cancer-stem-cell-specific antibody
JP2017535516A (ja) 固形がんおよび／またはその転移を処置する方法、そのための薬剤、ならびに固形がんおよび／またはその転移処置の臨床転帰を予測する方法
HK40073153A (en) Combination therapy
AU2012310086B2 (en) Antibodies directed against signal peptides, methods and uses thereof
HK40073153B (zh) 联合治疗
US20250134975A1 (en) Cancer vaccine comprising epitope of c-met and use thereof
TW202528342A (zh) Ｈｌａ／癌症抗原ｐｖｔ１衍生胜肽複合體特異性抗體
JP2025531837A (ja) 特定の患者群の組合せ処置及び癌の処置のための投薬レジメンにおいて使用される抗ｇｄｆ１５抗体
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
KR20250171308A (ko) 베타-카테닌 길항제의 투여 및 사용 방법
CN121925268A (zh) 疫苗组合物及其用途
Jr et al. A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
HK1238149A1 (en) A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073153

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant